SecurityGTN / Gray Television, Inc.
Chairman, President & CEOHOWELL HILTON H JR
IndustryTelevision Broadcasting Stations
Institutional Owners0
Common Shares Outstanding282,022,500 shares (as of 2018-06-30)
Related GTN.A / Gray Television, Inc.

Institutional Stock Ownership and Shareholders

Gray Television, Inc. (NYSE:GTN) has 0 institutional investors and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). Largest shareholders include .
Gray Television, Inc. (NYSE:GTN) ownership structure shows current positions in the company by institutions and funds, as well as latest changes in position size. Major shareholders can include individual investors, mutual funds, hedge funds, or institutions. The Schedule 13D indicates that the investor holds more than 5% of the company and intends to actively pursue a change in business strategy. Schedule 13G indicates a passive investment of over 5%. Green rows indicate new positions. Red rows indicate closed positions. Click the link icon to see the full transaction history.

Important Note!
Note: We do not currently have a CUSIP on file for this security. That means we are unable to search institutional fund filings (13F's) for this company, which means there may be institutional holders that we are unaware of. If you know the CUSIP or would like us to research and update this security, please let us know by leaving a message in the Welcome Group.
File DateFormInvestor Opt Prev
Prev Value
Current Value

Related Articles

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

EKSO: Ekso Bionics Holdings Analysis and Research Report

2018-09-18 - Asif

Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...

AGRX: Agile Therapeutics Analysis and Research Report

2018-09-18 - Asif

Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...

Related News Stories

IMAX Focuses on Home Entertainment With DTS Partnership

2018-09-05 zacks
IMAX Corporation (IMAX - Free Report) recently announced a partnership with DTS, a leader in audio technologies. It is aimed at improving home entertainment with enhanced visual and sound experiences. The partnership revolves around a certification and licensing program, which will combine “highest-end consumer electronics products with IMAX digitally re-mastered 4K HDR content and DTS audio technologies” for better home entertainment experience. (2-0)

GTN vs. SKYAY: Which Stock Should Value Investors Buy Now?

2018-09-05 zacks
Investors with an interest in Broadcast Radio and Television stocks have likely encountered both Gray Television (GTN - Free Report) and British Sky Broadcasting Group PLC (SKYAY - Free Report) . But which of these two stocks presents investors with the better value opportunity right now? Let's take a closer look.

Switching To Calls At Gray Television

2018-08-22 seekingalpha
Since I wrote my bullish piece on the company, shares are up ~40%, which is gratifying, but I must reevaluate the stock, as my target has been reached already.

Gray Television, Inc. (GTN) CEO Hilton Howell on Q2 2018 Results - Earnings Call Transcript

2018-08-12 seekingalpha
Gray Television, Inc. (NYSE:GTN) Q2 2018 Results Earnings Conference Call August 7, 2018 10:00 AM ET (4-0)

Wall Street Week Ahead: US broadcasters in line for political ad windfall

2018-08-11 malaymail
NEW YORK, Aug 11 — Local TV companies such as Sinclair Broadcast Group and Gray Television are set for a significant political advertising boost this year as candidates and special interest groups are spending heavily to woo voters in mid-term elections. (2-0)

Wall St Week Ahead-U.S. broadcasters in line for political ad windfall

2018-08-10 reuters
(Reuters) - Local TV companies such as Sinclair Broadcast Group (SBGI.O) and Gray Television (GTN.N) are set for a significant political advertising boost this year as candidates and special interest groups are spending heavily to woo voters in mid-term elections. (2-0)

Gray Television (GTN) Surpasses Q2 Earnings Estimates

2018-08-07 zacks
Gray Television (GTN - Free Report) just came out with quarterly earnings of $0.46 per share, beating the Zacks Consensus Estimate of $0.41 per share. This compares to earnings of $0.28 per share a year ago. These figures are adjusted for non-recurring items.

10 Killer Stocks to Buy That No One Knows About  

2018-08-06 investorplace
We have all heard about the big stocks a million times. That’s not to say they are bad investing prospects. Not at all. Amazon (NASDAQ:AMZN), for example, is an expensive stock with robust growth potential. (62-10)

Media Stocks' Earnings Lineup for Aug 7: GTN, TGNA & DIS

2018-08-06 zacks
We are now at the business end of second-quarter 2018 earnings season as 381 S&P 500 members — 81.2% of the index’s total market capitalization — have reported their quarterly numbers. Per the latest Earnings Preview, total earnings of these companies are up 25% on a year-over-year basis (80.1% beat EPS estimates) and total revenues have risen 10.4% (73.8% beat top-line estimates). Overall second-quarter earnings for S&P 500 companies are anticipated to be up 23. (1-0)